MTSR (metsera.com) Market Value to Book Value Ratio

Official company branding of Metsera, Inc. (MTSR)

The market valuation chart for Metsera Inc (MTSR) illustrates the ambitions of the biotech startup Metsera Inc, which is attracting leading peptide specialists through generous venture capital and stock options. The current figure stands at 22.04. The business is currently focused on its own clinical trials for weight-loss treatments with no plans for mergers. Meanwhile, financial stability remains absent, as funds are being spent on research prior to obtaining regulatory approvals.

MTSR Metsera Therapeutics: Market Value to Book Value in the range 02/01/2025 - 11/29/2025

Financial and market metric breakdowns for Metsera, Inc. (MTSR)

- price and consensus price forecast:
Price Chart Metsera Inc|MTSR - Fair Value Consensus
- market capitalization data:
Market Value Metsera Corp|MTSR - Full Business Value
- book capitalization data:
Book Value per Share Metsera|MTSR - Accounting Value of Company|Market Capitalization to Book Value Ratio metsera.com|MTSR - Company Total Assets
- debt and liquidity data:
Debt to Equity Metsera Inc|MTSR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Metsera Corp|MTSR - Company Total Debt|Debts to Book Capitalization Metsera Corp
Initial company analysis:Metsera Inc - MTSR
Original product of Metsera Corp

This indicator measures the proportion between the business's market value and its net assets, determining the extent to which investors are overpaying for fundamental capital. For Metsera Inc (MTSR), whose value is based on venture optimism and ambitions in obesity therapy, the ratio of current market capitalization to its balance sheet reflects the level of market confidence in the company's future clinical successes.

Main competitors

Market Value to Book Value Ratio Ascendis Pharma A/S ASND|MDGL (madrigalpharma.com) - Market Value to Book Value|Market Value to Book Value Ratio Corcept Therapeutics Incorporated CORT|Market Capitalization to Net Assets Rhythm Pharma|Akero Therapeutics Inc (AKRO) - Market Capitalization to Book Value Ratio|Market Value to Book Value MoonLake Corp (MLTX)|Market Capitalization to Book Value Ratio CRNX (Crinetics Pharmaceuticals)|newamsterdampharma.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Soleno Therapeutics, Inc. (SLNO)|FOLD: Market Value to Book Value|ETNB (89bio Corp) - Market Value to Book Value Ratio|Agios Corp (AGIO) - Market Cap to Net Assets Ratio|GPCR (Structure Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio mimedx.com (MDXG)|Rezolute (RZLT) - Market Cap to Net Assets Ratio|Market Value to Book Value LXRX (Lexicon Pharmaceuticals Inc)|MBX Bio - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Altimmune Pharma ALT|AARD (Aardvark Therapeutics Inc) - Market Capitalization to Book Value Ratio|sagimet.com (SGMT) - Market-to-Book Ratio|BIOA - Market Cap to Net Assets Ratio|Biomea Fusion Inc (BMEA) - Market Cap to Book Value Multiple|QNCX (Quince Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Fractyl Health, Inc|Market Capitalization to Book Value Ratio vTv Therapeutics Inc. (VTVT)|Market Value to Book Value Ratio ATPC (agapeatpgroup.com)|PLUR: Market Value to Book Value Ratio|Synlogic Inc. - Market-to-Book Ratio|LPCN - Market Value to Book Value Ratio|MTNB - Market Value to Book Value Ratio|Spruce Biosciences - Market Capitalization to Book Value Ratio|GLTO (galecto.com) - Market Capitalization to Book Value|CTCX: Market Value to Book Value Ratio|Market Capitalization to Book Value LUMO|Market Value to Book Value Ratio ONVO (Organovo Holdings Inc)|Market Cap to Net Assets Ratio RDUS (Radius Pharmaceuticals)